Skip to content
Home/Companies/Biotech/PegaOne
PegaOne

PegaOne

Biotech·France·Exited 2021·Held 2yr
Entry
2019
Hold
2yr
Exit
2021

Who owns PegaOne?

PegaOne is a French Biotech company, now owned by Centessa Pharmaceuticals, which acquired it in 2021 from Andera Partners.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
Andera Partners
Investor
Andera Partners
BioDiscovery 5 · 2017 · VC

Key facts

HQFrance
SectorBiotech
Websitepegaone.com
Exit Type
Trade Sale
Buyer
Centessa Pharmaceuticals
Exit Year
2021

More from BioDiscovery 5

Other portfolio companies in the same fund.

Amolyt Pharma
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to AstraZeneca
Evommune
Evommune
Exited 2025
BiotechFrance· 2021
to Public market (NYSE IPO ticker EVMN)
Nyxoah
Nyxoah
Active
MedTechBelgium· 2020
AgoMab
AgoMab
Exited 2026
BiotechFrance· 2019
to Public market (Nasdaq IPO ticker AGMB)
AM Pharma
AM Pharma
Active
BiotechNetherlands· 2019
Arvelle
Exited 2021
BiotechSwitzerland· 2019
to Angelini Pharma

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns PegaOne?

PegaOne is now owned by Centessa Pharmaceuticals, which acquired it in 2021 from Andera Partners.

When did Centessa Pharmaceuticals acquire PegaOne?

Centessa Pharmaceuticals acquired PegaOne in 2021, buying from Andera Partners.

Who did PegaOne sell to?

Andera Partners sold PegaOne to Centessa Pharmaceuticals in 2021 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue